Inovio Pharmaceuticals(US:INO) Globenewswire·2026-02-10 17:00Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking to recover damages for affected investors [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Inovio and its officers made materially false and misleading statements regarding the company's business and operations throughout the Class Period [3]. - Specific allegations include that Inovio lacked sufficient information to justify the eligibility of the INO-3107 Biologics License Application (BLA) for FDA accelerated approval or priority review [3][8]. - Additional claims state that manufacturing for Inovio's CELLECTRA device was deficient, and thus, the submission of the INO-3107 BLA to the FDA by the second half of 2024 was unlikely [8]. Group 2: Investor Participation - Investors who purchased Inovio securities during the Class Period are encouraged to join the lawsuit, with a deadline to request lead plaintiff status by April 7, 2026 [2][3]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if the lawsuit is successful [4]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5]. - The firm's mission focuses on restoring investor capital and ensuring corporate accountability to maintain market integrity [5].